Harvard Health Letter

News briefs: Combination therapy may be better for one common lung cancer

For people with non-small cell lung cancer that carries a mutation in the gene KRAS, a combination of the drug selumetinib and the chemotherapy drug docetaxel may be more effective than chemotherapy alone.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In